Advertisement
Search for

Volume 1, Issue 3, Pages 229-236 (May 2003)


View previous. 12 of 16 View next.

An evidence-based approach to studies of the natural history of gastrointestinal diseases: Recurrence of symptomatic Crohn's disease after surgery☆☆

James D. Lewis*, Philip Schoenfeld§, Gary R. Lichtenstein*

Patients with chronic disorders frequently ask about the prognosis of their disease. In some cases, this prognostic information may also guide management decisions. For example, a patient with Crohn's pancolitis may be willing to undergo colectomy if prognosis studies demonstrate that Crohn's disease is unlikely to return after surgery. However, if Crohn's disease is likely to return in the small intestine shortly after surgery, the patient may be less willing to agree to surgery. Before these questions about prognosis can be answered, appropriately designed studies must be completed and systematically appraised. This article, the third in the evidence-based medicine (EBM) series, provides an EBM framework to critically assess the design and results of a study about prognosis. This article examines the prognosis after colectomy for Crohn's colitis and follows the format of other EBM articles about prognosis. The EBM concepts have been expanded from previous articles, and examples from the gastroenterology literature have been used.

* Division of Gastroenterology, Department of Medicine

 Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

§ Division of Gastroenterology, University of Michigan School of Medicine and Veterans Affairs Center for Excellence in Health Services Research, Ann Arbor, Michigan

 Address requests for reprints to: James D. Lewis, M.D., MSCE, University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, 7th Floor Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021. e-mail: jlewis@cceb.med.upenn.edu; fax: (215) 573-5325.

☆☆ Dr. Lewis has served as a paid consultant to GlaxoSmithKline, Centocor, and Shire, and he has received research support from GlaxoSmithKline and Centocor. Dr. Lichtenstein has received honoraria from Centocor, GlaxoSmithKline, Shire Pharmaceuticals, AstraZeneca, Procter and Gamble, Salix, and Prometheus Laboratories, and he has received research support from Centocor. Dr. Schoenfeld has served as a paid consultant to AstraZeneca and Procter and Gamble.

 1542-3565/03/$30.00

PII: S1542-3565(03)70040-8


View previous. 12 of 16 View next.

Advertisement